REN and hypertensive disorder: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin–angiotensin–aldosterone system (RAAS) inhibitors treatment.